Cargando…
PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
BACKGROUND: Immune checkpoint inhibitors and chimeric antigen receptor (CAR)-based therapies have transformed cancer treatment. Recently, combining these approaches into a strategy of PD-L1-targeted CAR has been proposed to target PD-L1(high) tumors. Our study provides new information on the efficac...
Autores principales: | Bajor, Malgorzata, Graczyk-Jarzynka, Agnieszka, Marhelava, Katsiaryna, Burdzinska, Anna, Muchowicz, Angelika, Goral, Agnieszka, Zhylko, Andriy, Soroczynska, Karolina, Retecki, Kuba, Krawczyk, Marta, Klopotowska, Marta, Pilch, Zofia, Paczek, Leszek, Malmberg, Karl-Johan, Wälchli, Sébastien, Winiarska, Magdalena, Zagozdzon, Radoslaw |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796262/ https://www.ncbi.nlm.nih.gov/pubmed/35078921 http://dx.doi.org/10.1136/jitc-2021-002500 |
Ejemplares similares
-
PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress
por: Klopotowska, Marta, et al.
Publicado: (2022) -
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
por: Marhelava, Katsiaryna, et al.
Publicado: (2019) -
The Tumor Microenvironment—A Metabolic Obstacle to NK Cells’ Activity
por: Domagala, Joanna, et al.
Publicado: (2020) -
P1376: IDENTIFICATION OF SURFACEOME CHANGES IN CD19 CAR-T THERAPY-RESISTANT LYMPHOMA CELLS
por: Krawczyk, Marta, et al.
Publicado: (2023) -
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
por: Retecki, Kuba, et al.
Publicado: (2021)